DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
FactSet - 2 Zoetis - 2 Elanco - 1 Jeff Simmons - 1 Simmons - 1 Credelio - 1 Cornell University's Richard P - 1 Chris Schott - 1
Top related locs:
U.S parasiticides
Top related orgs:
Merck - 1 CNBC - 1 ELAN - 1 Riney Canine Health - 1 JPMorgan - 1 Argus - 1 Idexx Laboratories - 1 U.S . Food - 1

Search resuls for: "Credelio"


2 mentions found


☆ Elanco's $1.3 billion deal may give the animal health company more flexibility as product launches ramp up
  + stars: | 2024-02-06 | by ( Christina Cheddar Berk | In | ) www.cnbc.com   time to read: +6 min
Elanco Animal Health's decision to sell its aqua division will narrow its focus on pet health and livestock sustainability, as management prepares to launch several new products this year. ELAN 1Y mountain Elanco stock over the past year. One area it identified is pet health, a $15 billion market that has benefited from increasing pet ownership, especially among people who see their pets as family and value their animals' health care. 'Flexibility' to invest behind launches The product launches will also give Elanco a chance to prove itself. The pet health business is very competitive and, once approved, Zenrelia will compete directly with rival Zoetis' Apoquel.
Persons: Elanco, Jeff Simmons, Simmons, Credelio, Cornell University's Richard P, FactSet, Chris Schott, ELAN, Schott, Jefferies, Glen Santangelo, Eli Lilly, Jasper Hellweg, Hellweg, Zenrelia, Zoetis, — CNBC's Michael Bloom Organizations: Merck, CNBC, ELAN, Riney Canine Health, JPMorgan, Argus Locations: U.S
☆ This animal health stock could gain nearly 30% as it ramps up sales of dog arthritis treatment
  + stars: | 2023-10-10 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +3 min
A recent survey conducted by Piper Sandler shows most of the 101 veterinarians it polled expect the prices they charge and the volume of patients they see to mostly hold up in the months ahead. While Piper Sandler "modestly" trimmed earnings estimates for 2024 for animal health-care companies Zoetis, Idexx Laboratories and Elanco Animal Health , Westenberg said Zoetis' products performed well in the survey. Solensia rang up $30 million in sales last year, but the opportunity for Librela is even bigger, according to the analyst. ZTS YTD mountain Even with the recent pullback in Zoetis stock, shares are up more than 18% year to date. In the Piper Sandler survey, few vets said they would pick the company's Credelio Quattro as their primary parasiticide when it is released.
Persons: Piper Sandler, David Westenberg, Westenberg, Librela, Solensia, Zoetis, FactSet, Quattro Organizations: Idexx Laboratories, U.S . Food, Drug Administration, Elanco Locations: parasiticides, U.S
0 next >>
Total: 2